Micro-Leads

Executive Summary

Micro-Leads is a private medical device company pioneering a closed-loop neuromodulation platform that enables high-resolution reading and writing into the nervous system. Founded in 2014 and headquartered in Cambridge, USA, the company develops minimally invasive devices for spinal cord stimulation, peripheral nerve stimulation, and brain-computer interfaces. Its technology overcomes the limitations of current low-resolution neuromodulation therapies, which often fail to provide adequate relief for chronic pain, movement disorders, and other neurological conditions. By combining precise sensing with targeted stimulation, Micro-Leads aims to deliver personalized, adaptive therapy that can improve outcomes across a range of indications. The platform's modular design and ability to interface with multiple neural targets position it as a versatile solution in the rapidly evolving neuromodulation market. While the company remains in the development stage, its innovative approach has the potential to address significant unmet needs and capture substantial market share if clinical and regulatory milestones are achieved.

Upcoming Catalysts (preview)

• Q1 2026FDA Investigational Device Exemption (IDE) approval for lead clinical trial in spinal cord stimulation75% success
• Q3 2026Completion of first-in-human feasibility study for peripheral nerve stimulation platform60% success
• Q2 2026Strategic partnership or licensing deal with a major neuromodulation or medical device company40% success